Trulive Medical Continues to Shine: Ranked Among Future Healthcare's 'Top 100 in Innovative Devices & Smart Manufacturing' for Consecutive Years

Founded in 2019, Trulive has consistently focused on the field of cardiovascular diseases, which have extremely high mortality and disability rates and remain an unmet need in the Chinese market. In response to the long-standing reliance on imported devices in key areas of advanced cardiovascular medical interventions in China, the company has spent years overcoming multiple "bottleneck" challenges in cardiovascular intervention. Its proprietary technology has achieved several "firsts in China" and "only in China" milestones. To date, two of the company’s products have been approved for marketing, while several others have completed clinical trials and entered the registration approval stage. Four products have received special review as innovative medical devices from the Chinese government and have successfully applied for multiple national key projects. With high-quality products and strong overall capabilities, Trulive's domestically produced advanced cardiovascular interventional medical devices continue to break through barriers, shatter overseas technological monopolies, and fill domestic gaps.

This time,Trulive Stands Out from Thousands of Companies to Be Selected for the "Top 100 List of Innovative Devices and Intelligent Manufacturing in Future Healthcare", which is a high recognition from industry organizations of Trulive's comprehensive strength, future development potential, and social value.

From Technological Catch-up to Technological Breakthrough: Trulive Medtech Demonstrates the Power of China-produced High-end Medical Devices through Continuous Innovation. In response to the global challenges of interventional cardiovascular disease treatment, the company is writing a new chapter of innovation in China with its strong capabilities, injecting robust momentum into the rise of China's healthcare industry.

-End-